Drug Development

Pharmaceuticals get U.S. government grant to evaluate hepatitis C drug in Russia

Published in Hepatitis Weekly, September 20th, 2004

SciClone Pharmaceuticals, Inc. (CLN) announced that its collaborative partner, Verta, Ltd. has been awarded a grant from the U.S. government to evaluate the therapeutic potential of SCV-07 in a hepatitis C virus (HCV) proof-of-concept trial in Russia.

Based on earlier studies showing the capability of SCV-07 to stimulate the immune system to fight disease, Verta will conduct this pilot HCV clinical trial to explore the potential anti-viral capabilities of SCV-07. SciClone has acquired the worldwide rights, outside of Russia, to SCV-07 from Verta and is conducting pre-clinical studies with the intention of filing an investigational new drug (IND) application in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-09-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry